The US Food and Drug Administration has approved a novel, two-drug tablet for adults living with HIV who have successfully suppressed the virus on their current therapy. The once-daily medication, IDVYNSO (doravirine/islatravir), offers a new treatment option that avoids entire classes of common antiretroviral drugs, potentially reducing long-term exposure to medication for a growing population aging with HIV.
The approval is based on data from two Phase 3 clinical trials involving over 700 virologically suppressed adults. In these studies, switching to IDVYNSO demonstrated non-inferior efficacy in maintaining viral suppression at 48 weeks compared to both the widely used three-drug regimen BIKTARVY and a variety of other standard antiretroviral therapies. The safety profile of the new regimen was generally comparable to these existing treatments.
IDVYNSO is distinctive as the first complete, once-daily two-drug regimen that is both tenofovir-free and does not contain an integrase strand transfer inhibitor (INSTI). This provides a new option for patients and clinicians seeking therapeutic diversity. "As the health needs of adults living with HIV change over time, IDVYNSO gives clinicians a new choice for HIV treatment," said Dr. Eliav Barr, chief medical officer at Merck Research Laboratories. The combination pairs doravirine, an established NNRTI, with islatravir, a next-generation nucleoside analog with a novel mechanism of action.
The therapy is indicated specifically for adults who are virologically suppressed on a stable regimen, with no history of treatment failure and no known resistance to doravirine. It is not recommended for use with other antiretrovirals and carries warnings about potential drug interactions and severe skin reactions. Patient advocates highlight the importance of such tailored options. "People aging with HIV face additional health challenges," said Carl Baloney, Jr. of AIDS United. "It is essential that management of HIV considers these factors."
With the FDA clearance secured, IDVYNSO is expected to be available in pharmacies after May 11. The approval marks a significant step in simplifying long-term HIV management, offering a potent regimen with fewer drugs and a different side effect profile, which may benefit patients managing comorbidities and other medications as they age.